Am J Clin Oncol

1. JOBIN K, Hannouf MB, Bahmanyar S, Naseer A, et al
   Effectiveness and Toxicity Burden of Pembrolizumab in Combination With Neoadjuvant Chemotherapy for Stage II/III Triple Negative Breast Cancer: A Real-World Analysis From Alberta, Canada.
   Am J Clin Oncol. 2026 Nov 12. doi: 10.1097/COC.0000000000001399.
   

   >> Share

   
   

   
   Am J Surg

2. BARRON-CERVANTES NM, Chang DC, Kelleher CM
   Beyond size: the role of growth rate in managing adolescent breast masses.
   Am J Surg. 2026;262:117204.
   

   >> Share

   
   

   
   Ann Surg Oncol

3. LEE AJT, Cheung BHH, Kwong A
   Refining Targeted Axillary Dissection in Expanded-Eligibility Cohorts: Addressing Technical Workflow, Localization, and Practical Realities in Higher Nodal Burden Breast Cancer.
   Ann Surg Oncol. 2026 Nov 9. doi: 10.1245/s10434-026-20709.
   

   >> Share

   
   
4. SULLIVAN S, Mott S, Nataliansyah MM, Mobley EM, et al
   ASO Visual Abstract: Recent National Trends in Time to Breast Cancer Surgery Before and After the COVID-19 Pandemic Onset and Predictors of Failure to Receive Timely Surgery.
   Ann Surg Oncol. 2026 Nov 9. doi: 10.1245/s10434-026-20838.
   

   >> Share

   
   
5. YANG D, Abdul-Ghani S, Miyagi M, Yamauchi H, et al
   ASO Author Reflections: Addressing Surgical Delays for Neighboring Hawaiian Island Breast Cancer Patients.
   Ann Surg Oncol. 2026 Nov 7. doi: 10.1245/s10434-026-20888.
   

   >> Share

   
   
6. CHEN JH, Hunt KK, Rauch R, Guirguis MS, et al
   Predictors of Response to Neoadjuvant Systemic Therapy and Survival in Patients with cN1 Breast Cancer.
   Ann Surg Oncol. 2026 Nov 7. doi: 10.1245/s10434-026-20848.
   

   >> Share

   
   
7. FRASER K, Wilbers A, Reyes J, Helmer SD, et al
   ASO Visual Abstract: Choosing Wisely in Rural America: Surgical Management of the Axilla in Elderly Patients with Clinically Node-negative, Hormone Receptor-positive Invasive Breast Cancer.
   Ann Surg Oncol. 2026 Nov 6. doi: 10.1245/s10434-026-20856.
   

   >> Share

   
   

   
   BMC Cancer

8. ANANGA NOA SA, Dina Bell E, Anaba D, Ndengue CP, et al
   FOSL2 expression in histologically diagnosed breast cancer: first immunohistochemical evidence from Cameroon.
   BMC Cancer. 2026;26:1381.
   

   >> Share

   
   
9. POLANCO ER, Moustafa TE, Balcioglu O, Scherer SD, et al
   Determination of drug sensitivity in patient derived models of breast cancer by multiparametric quantitative phase imaging.
   BMC Cancer. 2026;26:1384.
   

   >> Share

   
   
10. WASTI SA, Gill S, Jamshed A, Noor M, et al
    Real-world effectiveness and safety of neoadjuvant pembrolizumab in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2026;26:1392.
    

    >> Share

    
    
11. KIPKOECH M, Beck CM, Jaeger A, Blume K, et al
    Linking dietary-derived arsenic exposure to blood serum arsenic burden, potential food sources, and breast cancer risk in the EPIC-Heidelberg cohort.
    BMC Cancer. 2026;26:1406.
    

    >> Share

    
    
12. KAVGACI G, Sahin TK, Guduk N, Sirvan F, et al
    Potential prognostic value of the free T3/T4 ratio in HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.
    BMC Cancer. 2026;26:1394.
    

    >> Share

    
    
13. ZHANG S, Dong S, Chen Y, Yu Y, et al
    Combined morphology and distribution features for risk stratification in pathology-enriched BI-RADS 4A/4B microcalcifications.
    BMC Cancer. 2026;26:1385.
    

    >> Share

    
    
14. SUN W, Wang W, Zhang Q, Zhao J, et al
    Integrating a Ripple Filter into Pencil Beam Scanning Proton Therapy for Breast Cancer: from Dosimetric Feasibility to Acute Toxicity Assessment.
    BMC Cancer. 2026;26:1386.
    

    >> Share

    
    
15. WANG X, Liu S, Tang L
    Dynamic changes in ER, PR, HER2, Ki-67, and AR before and after neoadjuvant therapy in breast cancer and their clinicopathological significance: a single-center real-world study.
    BMC Cancer. 2026;26:1375.
    

    >> Share

    
    
16. OMRANIPOUR R, Bayat M, Alipour S, Banigol F, et al
    Association between neoadjuvant and adjuvant chemotherapy and severity of breast cancer-related lymphedema following axillary lymph node dissection.
    BMC Cancer. 2026;26:1369.
    

    >> Share

    
    

    
    Breast Cancer

17. KOTANI H, Isogai A, Nakakami A, Kataoka A, et al
    Feasibility and safety of intraoperative photodynamic diagnosis using 5-aminolevulinic acid in breast cancer surgery.
    Breast Cancer. 2026 Nov 6. doi: 10.1007/s12282-026-01934.
    

    >> Share

    
    
18. IWAMOTO T, Uemura Y, Ishikawa T, Jo A, et al
    Longitudinal PRO-CTCAE assessment in patients with HR+/HER2 - metastatic breast cancer initiating palbociclib: feasibility and symptom trajectories in a multicenter prospective cohort study.
    Breast Cancer. 2026 Nov 6. doi: 10.1007/s12282-026-01936.
    

    >> Share

    
    
19. KIYOHARA H, Hanamura T, Sagara Y, Miyashita M, et al
    Real-world outcomes of everolimus-based therapy after CDK4/6 inhibitor therapy in ER-positive/HER2-negative metastatic breast cancer: a multicenter registry-based study.
    Breast Cancer. 2026 Nov 10. doi: 10.1007/s12282-026-01931.
    

    >> Share

    
    
20. KAWAMURA C, Iwagami M, Bando H
    Claims-defined adrenal insufficiency, hypothyroidism, and type 1 diabetes after immune checkpoint inhibitor initiation in patients with triple-negative breast cancer in Japan.
    Breast Cancer. 2026 Nov 11. doi: 10.1007/s12282-026-01940.
    

    >> Share

    
    

    
    Breast Cancer (Dove Med Press)

21. HUANG Z, Wortelboer N, Beaufort CM, Ortak SN, et al
    BCAR4, BCAR3 and EGFR Display Different Degrees of Cross-Resistance to Endocrine Mono- and Combination Therapies in Hormone Receptor Positive, HER2 Negative Breast Cancer.
    Breast Cancer (Dove Med Press). 2026;18:604019.
    

    >> Share

    
    
22. WU J, Zhang Y, Wang Q, Zhang J, et al
    Dual Primary Malignancies in Breast Cancer: Clinical Characteristics and Survival Predictors Among Hakka Women in Meizhou.
    Breast Cancer (Dove Med Press). 2026;18:645434.
    

    >> Share

    
    
23. CHEN Y, Song B, Ma Y
    The Cathepsin Network: Multifaceted Regulators and Emerging Therapeutic Targets in Breast Cancer.
    Breast Cancer (Dove Med Press). 2026;18:635861.
    

    >> Share

    
    
24. REN H, Chi W, Han X, Guo L, et al
    Two Niches, One Disease: Brain and Leptomeningeal Metastases in Breast Cancer: A Narrative Review.
    Breast Cancer (Dove Med Press). 2026;18:657423.
    

    >> Share

    
    

    
    Breast Cancer Res

25. LIU W, Zhang H, Zhang L, Wang W, et al
    Bacterial lipopolysaccharide mediates the interplay between tumor microbiome and immune microenvironment in breast cancer: development of a prognostic risk score.
    Breast Cancer Res. 2026;28:190.
    

    >> Share

    
    
26. CHICA-PARRADO MR, Onieva JL, Ribelles N, Godoy A, et al
    Molecular and clinical predictors of NAC response and relapse in HR+/HER2- early breast cancer.
    Breast Cancer Res. 2026;28:189.
    

    >> Share

    
    
27. JOHNS L, Brayley M, Frost R, Coulson P, et al
    Breast density and risk factors for interval and screen-detected breast cancers: a case-case analysis of the Breast Cancer Now Generations Study, UK.
    Breast Cancer Res. 2026;28:191.
    

    >> Share

    
    
28. HU Z, Zheng H, Jin C, Shang G, et al
    CD39-associated myeloid-T-cell coordination within an immunoregulatory neighborhood linked to treatment resistance in triple-negative breast cancer.
    Breast Cancer Res. 2026;28:192.
    

    >> Share

    
    
29. BOTTOSSO M, Griguolo G, Trovo L, Tognazzo S, et al
    Patterns of metastasis according to germline BRCA1/2 mutation status in patients with HER2-negative metastatic breast cancer.
    Breast Cancer Res. 2026;28:193.
    

    >> Share

    
    

    
    Breast Cancer Res Treat

30. NSUBAYI CK, Vidal GA, Kurian AW, Rehnquist MK, et al
    Real-world patient experiences in HR+/HER2- metastatic breast cancer: a study of symptom and side effect reporting by patients and physicians.
    Breast Cancer Res Treat. 2026;220:33.
    

    >> Share

    
    
31. HWANG YH, Lee SB, Kim J, Chung IY, et al
    Chemoendocrine therapy versus tamoxifen with ovarian function suppression in women with node-positive breast cancer.
    Breast Cancer Res Treat. 2026;220:31.
    

    >> Share

    
    
32. KARLSSON P, Sharifi MN, Holmberg E, Bakhtiar H, et al
    The landscape of cell surface target expression in treatment resistant early-stage breast cancer.
    Breast Cancer Res Treat. 2026;220:34.
    

    >> Share

    
    
33. ABOUSHAWAREB H, Mohamed AW, Alghzawi HM, Helbawy AE, et al
    Pertuzumab in HER2-positive breast cancer: a systematic review and meta-analysis of randomized controlled trials.
    Breast Cancer Res Treat. 2026;220:30.
    

    >> Share

    
    
34. ZHANG M, Qin Y, Wan J, Tian Z, et al
    Dose-dense neoadjuvant bi-weekly nab-paclitaxel followed by epirubicin-cyclophosphamide versus bi-weekly docetaxel followed by epirubicin-cyclophosphamide in patients with HR+/HER2- early breast cancer: a multicentre, randomised, phase III trial.
    Breast Cancer Res Treat. 2026;220:32.
    

    >> Share

    
    

    
    Breast J

35. CUKIER M, Pons S, Espino J, Ruiz M, et al
    SCOUT Radar Localization System-Guided Excision of Nonpalpable Breast Lesions: Initial Experience in a Latin American Population.
    Breast J. 2026;2026:6764918.
    

    >> Share

    
    
36. CHEN Z, Sun Q
    Brain Metastasis of Triple-Negative Breast Cancer: Mechanisms and Emerging Therapeutic Strategies.
    Breast J. 2026;2026:5914207.
    

    >> Share

    
    

    
    Cancer Cell

37. XU YZ, Wu XR, Qiu ZY, Li YW, et al
    Decoding neutrophil spatial heterogeneity and clinical implications in breast cancer.
    Cancer Cell. 2026;44:2249-2266.
    

    >> Share

    
    
38. PEI S, Ng LG
    Neutrophils are known by their neighbors in breast cancer.
    Cancer Cell. 2026;44:2129-2131.
    

    >> Share

    
    

    
    Cancer Epidemiol Biomarkers Prev

39. CHOI S, Lee D, Lee EG, Han JH, et al
    Socioeconomic Disparities in Breast Cancer Diagnosis, Treatment and Survival: Analysis of the Korean K-CURE cohort.
    Cancer Epidemiol Biomarkers Prev. 2026.
    

    >> Share

    
    

    
    Clin Breast Cancer

40. LI GQ, Kemu QLY, He XZ, Zhou J, et al
    Differential Impact of Postoperative Radiotherapy on Survival Across Clinical Treatment Score Post-5 Years Risk Categories in Early-Stage Luminal Breast Cancer After Breast-Conserving Surgery.
    Clin Breast Cancer. 2026;26:13-20.
    

    >> Share

    
    
41. SKELLY EA, Stevenson E, Tsai M, Gordon D, et al
    Increasing Specialty Menopause Referrals for Premenopausal Breast Cancer Patients: A Quality Improvement Initiative.
    Clin Breast Cancer. 2026;26:83-91.
    

    >> Share

    
    
42. ZHOU Y, Lu X, Geng W, Liu F, et al
    Distinct Trajectories of Patient-reported Outcome Radiation Dermatitis in Breast Cancer Patients Undergoing Radiotherapy: A Prospective Longitudinal Study.
    Clin Breast Cancer. 2026;26:7-12.
    

    >> Share

    
    
43. CURIGLIANO G, Castelo-Branco L, Muller V, Harbeck N, et al
    2026 Key European Guideline Changes for Metastatic Breast Cancer and Their Impact on Practice-Commentary Based on a Virtual Focus Group.
    Clin Breast Cancer. 2026;26:74-82.
    

    >> Share

    
    
44. FRANCIS AV, Savard MF, Ng TL, Hilton J, et al
    Evaluating Physician Perspectives on Neoadjuvant Immunotherapy and Chemotherapy for Early-Stage Triple-Negative Breast Cancer.
    Clin Breast Cancer. 2026;26:58-65.
    

    >> Share

    
    

    
    Clin Cancer Res

45. CHEN D, Wang N, Xu F, Xia W, et al
    Palbociclib, Fulvestrant, Trastuzumab, and Pyrotinib for Patients with Advanced Breast Cancer with Brain Metastases: A Prospective Multicenter Phase 2 Trial.
    Clin Cancer Res. 2026 Nov 11. doi: 10.1158/1078-0432.CCR-26-2610.
    

    >> Share

    
    

    
    Clin Exp Metastasis

46. FARES J, Kanojia D, Petrosyan E, Tobias AL, et al
    Mapping intratumoral coverage of neural stem cell-delivered anti-HER2 antibody in breast cancer brain metastasis.
    Clin Exp Metastasis. 2026;43:64.
    

    >> Share

    
    

    
    Eur J Surg Oncol

47. GUC H, Guc ZG, Dongelli H, Demirdover C, et al
    Is it the reconstruction or the complication? Factors associated with time to adjuvant chemotherapy after breast cancer surgery.
    Eur J Surg Oncol. 2026;53:112355.
    

    >> Share

    
    
48. CHANG YK, Kwong A
    Percutaneous cryoablation for local control of breast cancer in patients unsuitable for conventional surgery: a prospective study.
    Eur J Surg Oncol. 2026;53:112213.
    

    >> Share

    
    

    
    Eur Radiol

49. VARGAS IV, Mayerhoefer ME, Gemignani ML, Zhi I, et al
    Impact of [(18)F]fluoroestradiol PET/CT on clinical management in patients with estrogen receptor-positive breast cancer: a systematic review and meta-analysis.
    Eur Radiol. 2026 Nov 7. doi: 10.1007/s00330-026-13051.
    

    >> Share

    
    
50. CICCIARELLI F, Rizzo V, Buccilli D, De Nardo C, et al
    Multiparametric MRI to predict response to neoadjuvant chemotherapy in breast cancer: Are we ready for NacBI-RADS?
    Eur Radiol. 2026 Nov 10. doi: 10.1007/s00330-026-12805.
    

    >> Share

    
    
51. ALVAREZ-BENITO M
    NacBI-RADS and prediction of response to neoadjuvant systemic therapy in breast cancer: challenges and future prospects.
    Eur Radiol. 2026 Nov 10. doi: 10.1007/s00330-026-12995.
    

    >> Share

    
    

    
    Int J Radiat Oncol Biol Phys

52. XU F, Huang X, Cai G, Ou D, et al
    Early toxicity and dosimetry compliance of hypofractionated vs. conventional fractionated comprehensive regional nodes irradiation in breast cancer (HARVEST).
    Int J Radiat Oncol Biol Phys. 2026 Nov 12:S0360-3016(26)04452.
    

    >> Share

    
    

    
    Oncology

53. KIM JJ, Yoon J, Jung YJ, Lee S, et al
    Comparison of quality of life between docetaxel and weekly paclitaxel in the neoadjuvant or adjuvant treatment of breast cancer.
    Oncology. 2026 Nov 9:aebag013. doi: 10.1159.
    

    >> Share

    
    

    
    PLoS Comput Biol

54. WEN H, Shen Q, Zhang S
    SpatioCAD: Context-aware graph diffusion model for pinpointing spatially variable genes in heterogeneous tissues.
    PLoS Comput Biol. 2026;22:e1014923.
    

    >> Share

    
    

    
    PLoS One

55. CHEN J, Dai J, Zhou P, Yuan Y, et al
    Effect of different axillary management strategies on survival in elderly patients (>/=70 Years) with early-stage breast cancer and 1-2 positive lymph nodes, stratified by risk factors.
    PLoS One. 2026;21:e0353331.
    

    >> Share

    
    
56. LIN S, Zheng Y, Chen Z, Patrice MD, et al
    Uncovering the immune microenvironmental atlas of breast cancer molecular subtypes based on single-cell transcriptomics.
    PLoS One. 2026;21:e0361987.
    

    >> Share

    
    
57. EMAELY TS, Mremi A, Msoka EF, Mutashobya R, et al
    Male breast cancer in Northern Tanzania: Clinicopathology and predictors of two-year survival (2016-2022).
    PLoS One. 2026;21:e0361615.
    

    >> Share

    
    

    
    Radiol Imaging Cancer

58. MOFFETT L, Barnett AJ, Ou YJ, Kim G, et al
    Interpretable Artificial Intelligence for the Assessment of Mass Margin and Malignancy on Mammograms: A Reader Study.
    Radiol Imaging Cancer. 2026;8:e250736.
    

    >> Share

    
    

    
    Radiology

59. DENG T, Moon WK, Yan C, Xiang H, et al
    Glandular Tissue Component at Preoperative Breast US and Recurrence Risk in Invasive Breast Cancer.
    Radiology. 2026;321:e260681.
    

    >> Share

    
    

    
    Science

60. HE S, Thennavan A, Wei R, Bai S, et al
    A cellular atlas of the preinvasive breast cancer microenvironment.
    Science. 2026 Nov 12:eaef4622. doi: 10.1126/science.aef4622.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share